Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Regulatory and legal status FDA classification As of April 2026, BPC-157 is a Category 2 bulk drug substance under FDA's framework for compounding under Section 503A
Monitoring: Blood Work & Baseline Testing BPC-157 blood work should be considered for anyone running laboratory protocols or cycles
Its not recommended to administer the injection in the lower leg
The agency has scheduled a Pharmacy Compounding Advisory Committee review for July 2026 to determine whether BPC-157 will be permitted on the 503A bulks list
Researchers choose BPC-157 for its uniquely broad profile: it accelerates tissue repair , drives new blood-vessel formation , and protects gastrointestinal lining , all within a single peptide
Just be sure you stick to quality supplement brands that dont contain weird fillers
